SamuelAaronGoldlustMD

Neurology • Kansas City, MO

Neurooncology

Medical Director, Neuro-Oncology

Join to view full profile

Dr. Goldlust is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Goldlust's full profile

Already have an account?

Office
4401 Wornall Road
Kansas City, MO 64111
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Neuro-Oncology, 2009 - 2011
NYU Grossman School of MedicineResidency, Neurology, 2006 - 2009
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 2005 - 2006
Ohio State University College of MedicineClass of 2005

Certifications & Licensure

KS State Medical License 2023 - 2024
MO State Medical License 2023 - 2024
NJ State Medical License 2011 - 2023
NY State Medical License 2008 - 2011
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma Start of enrollment: 2013 Aug 01
Suspended
Phase 1, Phase 2
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
Terminated
Phase 2
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Start of enrollment: 2021 May 18
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.
Prashasti Agrawal, Kevin A David, Zhengming Chen, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, My...> ;Leukemia & Lymphoma. 2023 May 1
1 citations
Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19).
Jay-Jiguang Zhu, Samuel A Goldlust, Lawrence R Kleinberg, Jérôme Honnorat, Nancy Ann Oberheim Bush, Zvi Ram> ;Discover. Oncology. 2022 Oct 14
8 citations
Tetrodotoxin for Chemotherapy-Induced Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Finding Trial
Samuel Goldlust, Mojgan Kavoosi, Jennifer Nezzer, Mehran Kavoosi, Walter Korz, Kenneth Deck> ;Toxins. 2021 Mar 25
8 citations
Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs
Catherine Do, Emmanuel L. P. Dumont, Martha Salas, Angelica Castano, Huthayfa Mujahed, Leonel Maldonado, Arunjot Singh, Sonia DaSilva-Arnold, Govind Bhagat, Soren Lehm...> ;Genome Biology. 2020 Jun 29
47 citations
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
Jiayi Huang, Rekha Chaudhary, Adam L. Cohen, Karen Fink, Samuel Goldlust, John A. Boockvar, Prakash Chinnaiyan, Leping Wan, Stephen Marcus, Jian Campian> ;Journal of Neuro-Oncology. 2019 Feb 15
8 citations
Correction: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma [J Transl Med., 16, (...
Linda M. Liau, Keyoumars Ashkan, David Tran, Jian Campian, John E. Trusheim, Charles S. Cobbs, Jason Heth, Michael Salacz, Sarah A. Taylor, Stacy D. D’Andre, Fabio M. ...> ;Journal of Translational Medicine. 2018 Jun 29
121 citations
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M Liau, Keyoumars Ashkan, David D Tran, Jian L Campian, John E Trusheim, Charles S Cobbs, Jason A Heth, Michael Salacz, Sarah Taylor, Stacy D D'Andre, Fabio M Iw...> ;Journal of Translational Medicine. 2018 May 29
3 citations
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.
Michael Weller, Nicholas Butowski, David Tran, Lawrence Recht, Michael Lim, H Hirte, Lynn S. Ashby, Laszlo Mechtler, Samuel Goldlust, Fabio M. Iwamoto, Jan Drappatz, D...> ;The Lancet. Oncology. 2017 Dec 1
35 citations
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared ...
Jay-Jiguang Zhu, Petya Demireva, Andrew A. Kanner, Susan C. Pannullo, Maximilian Mehdorn, Nicholas Avgeropoulos, Andrea Salmaggi, Antonio Silvani, Samuel Goldlust, Car...> ;Journal of Neuro-Oncology. 2017 Aug 28
Rindopepimut with Temozolomide for Patients with Newly Diagnosed, EGFRvIII-Expressing Glioblastoma (ACT IV): A Randomised, Double-Blind, International Phase 3 Trial
Nicholas Butowski, Lawrence D Recht, Michael J Yellin, Samuel A Goldlust, Fabio Iwamoto, Jan Drappatz, John H Sampson, Lynn Ashby, Laszlo Mechtler, Michael Lim> ;The Lancet.
14 citations
Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors
Samuel Goldlust, Robert Cavaliere, Herbert B. Newton, Meier Hsu, Lisa M. DeAngelis, Tracy T. Batchelor, Mark R. Gilbert, Andrew B. Lassman> ;Journal of Neuro-Oncology. 2012 Apr 1
18 citations
Seizure Prophylaxis and Melanoma Brain Metastases
Samuel Goldlust, Meier Hsu, Andrew B. Lassman, K. S. Panageas, Edward K. Avila> ;Journal of Neuro-Oncology. 2012 Feb 5
43 citations
Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience
Mustafa Khasraw, Andrei I. Holodny, Samuel Goldlust, Lisa M. DeAngelis> ;Annals of Oncology. 2012 Feb 1
4 citations
Headache in patients with cancer
Samuel Goldlust, Jerome J. Graber, Dana Bossert, Edward K. Avila> ;Current Pain and Headache Reports. 2010 Oct 8
28 citations
Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors.
Herbert B. Newton, Jennifer Dalton, Samuel A. Goldlust, Dennis K. Pearl> ;Journal of Neuro-Oncology. 2007 Apr 13
85 citations
Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients
Herbert B. Newton, Samuel A. Goldlust, Dennis K. Pearl> ;Journal of Neuro-Oncology. 2006 Mar 16
31 citations
Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas.
Narendra Nathoo, Samuel Goldlust, Michael A. Vogelbaum> ;Neurosurgery. 2004 Jun 1
23 citations
Randomized prospective comparison of forced air warming using hospital blankets versus commercial blankets in surgical patients.
Abdallah Kabbara, Samuel A. Goldlust, Charles E. Smith, Joan F. Hagen, Alfred C. Pinchak> ;Anesthesiology. 2002 Aug 1
Join now to see all

Press Mentions

Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)May 11th, 2022
John Theurer Cancer Center Treats First Patient in U.S. With Investigational New Treatment for Brain CancerMarch 28th, 2022
Hackensack University Medical Center Foundation Celebrates Formal Investiture of Samuel A. Goldlust, M.D.December 4th, 2017
Join now to see all